Form 4: Janux Therapeutics Director Receives Equity Grant

Director Natasha Hernday was granted 5,500 restricted stock units and 15,500 stock options by Janux Therapeutics.

Summary

• Director Natasha Hernday acquired 5,500 restricted stock units (RSUs) on June 11, 2026.
• The director was also granted 15,500 stock options with an exercise price of $13.66 per share.
• The RSUs vest on the earlier of June 11, 2027, or the date of the next annual stockholder meeting.
• The stock options vest in equal monthly installments over 12 months, fully vesting by the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of options and vesting of RSUs.

Risks

• Continuous service requirements for vesting may impact the director's tenure or compensation structure.

Future Outlook

The equity grants are subject to continuous service requirements, with full vesting expected by the next annual meeting of stockholders.

Management Comments

• The grants represent a standard compensation structure for board members to ensure long-term alignment with company performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize board oversight and long-term strategic commitment.

Comparison to Industry Standards

• The use of a mix of RSUs and stock options is consistent with compensation packages for directors at mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common governance practices to ensure board continuity.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of RSUs on June 11, 2027, or the next annual meeting.
• Monthly vesting of stock options over the next 12 months.

Key Dates

Keywords

Janux Therapeutics, JANX, Form 4, Insider Trading, Equity Compensation, Director Compensation